1. Home
  2. UEC vs CRSP Comparison

UEC vs CRSP Comparison

Compare UEC & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Uranium Energy Corp.

UEC

Uranium Energy Corp.

HOLD

Current Price

$11.58

Market Cap

4.8B

ML Signal

HOLD

CRSP

CRISPR Therapeutics AG

HOLD

Current Price

$56.70

Market Cap

5.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UEC
CRSP
Founded
2003
2013
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Other Metals and Minerals
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.8B
5.8B
IPO Year
2008
2016

Fundamental Metrics

Financial Performance
Metric
UEC
CRSP
Price
$11.58
$56.70
Analyst Decision
Strong Buy
Buy
Analyst Count
5
17
Target Price
$18.95
$70.29
AVG Volume (30 Days)
7.9M
1.4M
Earning Date
06-01-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$66,837,000.00
$289,590,000.00
Revenue This Year
N/A
$807.72
Revenue Next Year
$220.11
$172.52
P/E Ratio
N/A
N/A
Revenue Growth
29737.95
9169.85
52 Week Low
$8.91
$44.12
52 Week High
$20.34
$78.48

Technical Indicators

Market Signals
Indicator
UEC
CRSP
Relative Strength Index (RSI) 50.39 53.95
Support Level $9.19 $50.45
Resistance Level $12.51 $59.61
Average True Range (ATR) 0.68 2.55
MACD 0.01 -0.01
Stochastic Oscillator 33.90 46.58

Price Performance

Historical Comparison
UEC
CRSP

About UEC Uranium Energy Corp.

Uranium Energy Corp is a uranium mining company engaged in the exploration, extraction, and processing of uranium and titanium concentrates across projects in the United States, Canada, and Paraguay. The Company operates through multiple segments, including uranium mining activities in Wyoming, Texas, Saskatchewan, and other regions, along with a corporate segment focused on investments and uranium inventory trading. It is expanding its portfolio of low-cost uranium projects in stable North American locations and operates a Wyoming-based ISR (In-Situ Recovery) Hub and Spoke platform. This platform is supported by two fully operational central processing plants and seven U.S. ISR uranium projects.

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Share on Social Networks: